^
Association details:
| Biomarker: | EZH2 A682G |
|---|---|
| Cancer: | Non-Hodgkin’s Lymphoma |
| Drug: | Tazverik (tazemetostat) (EZH2 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
Excerpt:
The Pfeiffer cell line (EZH2 A682G) showed a 20- to 300-fold increase in sensitivity to EPZ-6438, as measured by IC50 value and LCC, respectively, over the Y646-mutant cell lines.
DOI:
10.1158/1535-7163.MCT-13-0773
